Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | SRC | P12931 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL108503 | 1.00 | KDM1A (0.39) | KDM1AALOX15ALDH1A1PTPN1TSHR | |
| SCHEMBL27176381 | 1.00 | KDM1A (0.39) | KDM1AALOX15ALDH1A1PTPN1TSHR | |
| SCHEMBL108439 | 0.86 | KDM1A (0.44) | KDM1APTPN1 | |
| SCHEMBL108440 | 0.86 | KDM1A (0.44) | KDM1APTPN1 | |
| SCHEMBL23668765 | 0.83 | PTPN1 (0.53) | KDM1AALOX15ALDH1A1PTPN1KMT2A | |
| SCHEMBL11546006 | 0.83 | ALOX15 (0.35) | KDM1AALOX15ALDH1A1TSHRKMT2A | |
| SCHEMBL11546011 | 0.83 | ALOX15 (0.35) | KDM1AALOX15ALDH1A1TSHRKMT2A | |
| SCHEMBL2003932 | 0.81 | KDM1A (0.44) | KDM1AALOX15ALDH1A1PTPN1KMT2A | |
| SCHEMBL5855322 | 0.81 | ALOX15 (0.34) | KDM1AALOX15ALDH1A1TSHRKMT2A | |
| SCHEMBL11553469 | 0.81 | ALOX15 (0.34) | KDM1AALOX15ALDH1A1TSHRKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 164 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2463374-A2 | Isolated alcohol dehydrogenase enzymes and uses thereof | Bio Architecture Lab, Inc. (US) | 2012-06-13 | — | — | EP | claimed |
| EP-2195440-A2 | BIOFUEL PRODUCTION | Bio Architecture Lab, Inc. (US) | 2010-06-16 | — | — | EP | claimed |
| US-20090155873-A1 | BIOFUEL PRODUCTION | BIO ARCHITECTURE LAB, INC. (US) | 2009-06-18 | — | — | US | claimed |
| US-20090139134-A1 | BIOFUEL PRODUCTION | BIO ARCHITECTURE LAB, INC. (US) | 2009-06-04 | — | — | US | claimed |
| WO-2009046375-A2 | BIOFUEL PRODUCTION | BIO ARCHITECTURE LAB, INC. (US) | 2009-04-09 | — | — | WO | claimed |
| WO-2009046370-A2 | BIOFUEL PRODUCTION | BIO ARCHITECTURE LAB, INC. (US) | 2009-04-09 | — | — | WO | claimed |
| US-7105685-B2 | Viricides treating Human Immunodeficiency Viruses; antitumor agents | TRAVIS CRAIG R | 2006-09-12 | — | — | US | claimed |
| US-20040242870-A1 | Cannbichromene derivative; aids therapy | IMMUGEN PHARMACEUTICALS, INC. | 2004-12-02 | — | — | US | claimed |
| US-20030171372-A1 | Antiviral methods and compounds | IMMUGEN PHARMACEUTICALS, INC. (US) | 2003-09-11 | — | — | US | claimed |
| US-20030158191-A1 | Cannabinol derivatives | TRAVIS CRAIG R (US) | 2003-08-21 | — | — | US | claimed |
| US-6541510-B2 | Cannabichromene derivative is exposed to the virus, a host cell, or an infected cell under conditions sufficient to inhibit the replication or proliferation of the virus, especially HIV. | IMMUGEN PHARMACEUTICALS, INC. | 2003-04-01 | — | — | US | claimed |
| JP-2002539246-A | — | — | 2002-11-19 | — | — | JP | claimed |
| US-20020068738-A1 | Antiviral methods and compounds | IMMUGEN PHARMACEUTICALS, INC. | 2002-06-06 | — | — | US | claimed |
| WO-2002026728-A2 | ANTIVIRAL METHODS AND COMPOUNDS | IMMUGEN PHARMACEUTICALS, INC. (US) | 2002-04-04 | — | — | WO | claimed |
| EP-1189603-A2 | TREATMENT OF IMMUNE DISEASES LIKE HIV DISEASE AND NEOPLASTIC DISORDERS | Immugen Pharmaceuticals, Inc. (US) | 2002-03-27 | — | — | EP | claimed |
| US-6274635-B1 | ANTITUMOR AGENTS | IMMUGEN PHARMACEUTICALS INC. | 2001-08-14 | — | — | US | claimed |
| WO-2000056303-A2 | TREATMENT OF IMMUNE DISEASES | IMMUGEN PHARMACEUTICALS, INC. (US) | 2000-09-28 | — | — | WO | claimed |
| EP-3230463-B2 | RAPID PRETREATMENT | APALTA PATENTS OUE (EE) | 2025-07-16 | — | — | EP | disclosed |
| US-6274635-B1 | ANTITUMOR AGENTS | IMMUGEN PHARMACEUTICALS INC. | 2001-08-14 | — | — | US | disclosed |
| WO-2000056303-A2 | TREATMENT OF IMMUNE DISEASES | IMMUGEN PHARMACEUTICALS, INC. (US) | 2000-09-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030171372-A1 | Antiviral methods and compounds | MAVS, CNR1, ZC3HAV1 | KDM1A 2026/4885ALOX15 403/4885ALDH1A1 3995/4885 |
| US-20030158191-A1 | Cannabinol derivatives | CNR2, CNR1, GPR18 | KDM1A 2913/4885ALOX15 906/4885ALDH1A1 3703/4885 |
| US-20020068738-A1 | Antiviral methods and compounds | MAVS, CNR1, ZC3HAV1 | KDM1A 2026/4885ALOX15 403/4885ALDH1A1 3995/4885 |
| US-20040242870-A1 | Cannbichromene derivative; aids therapy | CNR1, CNR2, MKI67 | KDM1A 2439/4885ALOX15 118/4885ALDH1A1 2580/4885 |
| US-20090139134-A1 | BIOFUEL PRODUCTION | MGAM, DCXR, MANBA | KDM1A 3532/4885ALOX15 851/4885ALDH1A1 753/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.